Treatment strategies for HIV lipodystrophy

Area of Science:

• HIV/AIDS research
• Metabolic disorders
• Pharmacology

Background:

• HIV lipodystrophy, characterized by peripheral fat loss and central fat gain, presents limited treatment options.
• The condition's incidence is decreasing with the adoption of newer antiretroviral therapies.
• Specific nucleoside analogues (stavudine, zidovudine) and certain protease inhibitors are implicated in lipoatrophy.
• Central fat accumulation is linked to metformin and growth hormone, though effects are often transient and can worsen lipoatrophy.

Purpose of the Study:

• To review emerging treatment strategies for HIV lipodystrophy.
• To evaluate interventions for peripheral subcutaneous lipoatrophy and central fat accumulation.
• To assess the efficacy and sustainability of current and novel therapeutic approaches.

Main Methods:

• Literature review of studies on HIV lipodystrophy treatments.
• Analysis of clinical trial data and observational studies.
• Synthesis of evidence regarding antiretroviral drug effects and non-antiretroviral interventions.

Main Results:

• Antiretroviral regimens avoiding stavudine and zidovudine significantly protect against lipoatrophy.
• Cessation of implicated antiretroviral drugs leads to gradual improvement in established lipoatrophy.
• Thiazolidinediones, uridine, and pravastatin show potential but lack sustained effects on lipoatrophy.
• Metformin, growth hormone, and analogues effectively reduce central fat but can exacerbate lipoatrophy with transient benefits.
• Cosmetic surgery offers modest improvement for facial lipoatrophy.

Conclusions:

• Switching to antiretroviral regimens without stavudine or zidovudine is key for preventing lipoatrophy.
• Gradual improvement of established lipoatrophy occurs upon discontinuing offending antiretroviral agents.
• Currently, no medical intervention demonstrates sustained and substantial benefits for both lipoatrophy and visceral fat accumulation.